// App-Quantinova.ai

: Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Researchers

Presenter

  • Tim H. Brummendorf

Principal Investigators

  • Carlo Gambacorti-Passerini

  • Andreas Hochhaus

  • Jeff H. Lipton

  • Vamsi Kota

  • Michael W. Deininger

  • Eric Leip

  • Andrea Viqueira

  • Roxanne Ferdinand

  • Jorge E. Cortes

Medical Centers

  • Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation,Uniklinik RWTH Aachen,Aachen,Deutschland

  • Dept. of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

  • Klinik fur Innere Medizin II, Abt. Hamatologie und Intern. Onkologie, Universitatsklinikum, Jena, Germany

  • Hans Messner Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Division of Hematology and Hematologic Malignancies, University of Utah School of Medicine, Salt Lake City, UT

  • Pfizer Inc., Cambridge, MA

  • Pfizer Spain, Madrid, Spain

  • Pfizer Ltd, Walton-on-the-Hill, United Kingdom

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • Germany

  • Italy

  • Canada

  • United States

  • Spain

  • United Kingdom

Companies

  • Pfizer Inc.

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Bosutinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT02130557

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved